Drs. Jeffrey Esko and Dzung Le Join the Center for Nanomedicine

June 07, 2016
Jeffrey Esko, Ph.D. and  Dzung Le, M.D., Ph.D.

The Center for Nanomedicine enthusiastically welcomes two top-ranked research and clinical scientists as new members of our center.  Both will participate as inter-institutional adjunct professors.  Their expertise complements CNM biomedical research programs to identify the causes of disease at the nanoscale and molecular level needed to develop more effective diagnostics and therapeutics.

Dr. Jeffrey Esko, is a world expert in the molecular biology and therapeutic activities of proteoglycans.  These molecules include the most successful drug of all time-heparin, prescribed throughout the world in metric tons each year.  Dr. Esko is Co-Director of the Glycobiology Research and Training Center at UCSD, and a faculty member of the Department of Cellular and Molecular Medicine.  “My laboratory is increasing our interdisciplinary research aligned with the CNM and its biomedical programs including infectious diseases and sepsis.  We look forward to these important interactions” said Dr. Esko.  Dr. Dzung Le is a clinician scientist and UCSD faculty member in Pathology with expertise in hematology and blood coagulation. Dr. Le is also Director of the Special Coagulation Laboratory, and Associate Director of Transfusion Medicine.   Dr. Le stated “I am delighted to join the faculty of the CNM, I believe that our efforts to diagnose and treat patients with blood-borne diseases, often caused by infectious agents, will be synergistic with the ongoing biomedical research and technology development at the CNM.”.  CNM Director Dr. Jamey Marth welcomed these new members.  “We are building a critical mass of biomedical researchers aligned with the CNM.  The development of biomedical research expertise and infrastructure at UCSB remains an ongoing effort. In the interim, we can bring in the expertise and infrastructure needed from outside sources by collaborative mechanisms. The CNM is such a collaborative mechanism.   This will ensure that the CNM remains competitive in biomedical research.

Related Links